2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Sanofi, we had the pleasure of speaking with Robert Z. Orlowski, MD, PhD, about the phase 3 IMROZ trial (NCT03319667) investigating isatuximab-irfc (Sarclisa), bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Isa-VRd) vs VRd in patients with newly diagnosed, transplant-ineligible multiple myeloma. Dr Orlowski holds the Florence Maude Thomas Cancer Research Professorship in the Department of Lymphoma/Myeloma, is the director of the Section of Myeloma, and is a professor in the Department of Experimental Therapeutics in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Dr Orlowski discussed key efficacy data from IMROZ, the quality-of-life impact of Isa-VRd, and how the findings from this trial may pave the way for additional research with quadruplet regimens in the transplant-ineligible multiple myeloma setting.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Sanofi. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.